CD8A and hepatocellular carcinoma: The up-regulation of CXCL9/10/12/14 might improve outcomes of HCC patients through reinforcing immune surveillance of CD8+ T cells, NK cells, DCs, and Th1 cells, etc., while CXCL2 might mainly be through reducing MDSCs.